Leishmaniasis, as a tropical and subtropical disease, is endemic in more than 90 countries around the world. Today, cutaneous leishmaniasis (CL) that affects more than 1.5 million people per year lacks a definitive treatment approach. Imatinib is an anticancer drug that inhibits the abnormal function of Bcr-Abl due to its tyrosine kinase inhibitor, and that was the reason why the drug was tested for CL treatment because protein kinases are essential enzymes in the Leishmania genus. In this study, the L. major CL model of Balb/c mice was produced by injection of the cultured metacyclic form of parasite at the base of the tail. The possible recovery of CL ulcers and determination of the optimum dose of imatinib against Leishmania amastigotes were evaluated. A significant decrease was observed in mice treated with amphotericin B (positive control group) as well as imatinib 50 mg/kg compared to the unreceived drug, negative control group (P<0.05). This study could be promising in gaining insight into the potential of imatinib as an effective treatment approach against CL.
Citation: Mohsen Moslehi, Fatemeh Namdar, Mahsa Esmaeilifallah, Fariba Iraji, Bahareh Vakili, Fatemeh Sokhanvari, Seyed-Mohsen Hosseini, Faham Khamesipour, Zahra Sebghatollahi, Sayed-Hossein Hejazi. Study of therapeutic effect of different concentrations of imatinib on Balb/c model of cutaneous leishmaniasis[J]. AIMS Microbiology, 2020, 6(2): 152-161. doi: 10.3934/microbiol.2020010
[1] | Lovelesh Sharma . Brezis Nirenberg type results for local non-local problems under mixed boundary conditions. Communications in Analysis and Mechanics, 2024, 16(4): 872-895. doi: 10.3934/cam.2024038 |
[2] | Shu Wang . Global well-posedness and viscosity vanishing limit of a new initial-boundary value problem on two/three-dimensional incompressible Navier-Stokes equations and/or Boussinesq equations. Communications in Analysis and Mechanics, 2025, 17(2): 582-605. doi: 10.3934/cam.2025023 |
[3] | Yuxuan Chen . Global dynamical behavior of solutions for finite degenerate fourth-order parabolic equations with mean curvature nonlinearity. Communications in Analysis and Mechanics, 2023, 15(4): 658-694. doi: 10.3934/cam.2023033 |
[4] | Eleonora Amoroso, Angela Sciammetta, Patrick Winkert . Anisotropic $ (\vec{p}, \vec{q}) $-Laplacian problems with superlinear nonlinearities. Communications in Analysis and Mechanics, 2024, 16(1): 1-23. doi: 10.3934/cam.2024001 |
[5] | Leandro Tavares . Solutions for a class of problems driven by an anisotropic $ (p, q) $-Laplacian type operator. Communications in Analysis and Mechanics, 2023, 15(3): 533-550. doi: 10.3934/cam.2023026 |
[6] | Efstratios Stratoglou, Alexandre Anahory Simoes, Leonardo J. Colombo . Reduction in optimal control with broken symmetry for collision and obstacle avoidance of multi-agent system on Lie groups. Communications in Analysis and Mechanics, 2023, 15(2): 1-23. doi: 10.3934/cam.2023001 |
[7] | Farrukh Dekhkonov . On one boundary control problem for a pseudo-parabolic equation in a two-dimensional domain. Communications in Analysis and Mechanics, 2025, 17(1): 1-14. doi: 10.3934/cam.2025001 |
[8] | Xiao Han, Hui Wei . Multiplicity of the large periodic solutions to a super-linear wave equation with general variable coefficient. Communications in Analysis and Mechanics, 2024, 16(2): 278-292. doi: 10.3934/cam.2024013 |
[9] | Huiyang Xu . Existence and blow-up of solutions for finitely degenerate semilinear parabolic equations with singular potentials. Communications in Analysis and Mechanics, 2023, 15(2): 132-161. doi: 10.3934/cam.2023008 |
[10] | Yang Liu . Global attractors for a nonlinear plate equation modeling the oscillations of suspension bridges. Communications in Analysis and Mechanics, 2023, 15(3): 436-456. doi: 10.3934/cam.2023021 |
Leishmaniasis, as a tropical and subtropical disease, is endemic in more than 90 countries around the world. Today, cutaneous leishmaniasis (CL) that affects more than 1.5 million people per year lacks a definitive treatment approach. Imatinib is an anticancer drug that inhibits the abnormal function of Bcr-Abl due to its tyrosine kinase inhibitor, and that was the reason why the drug was tested for CL treatment because protein kinases are essential enzymes in the Leishmania genus. In this study, the L. major CL model of Balb/c mice was produced by injection of the cultured metacyclic form of parasite at the base of the tail. The possible recovery of CL ulcers and determination of the optimum dose of imatinib against Leishmania amastigotes were evaluated. A significant decrease was observed in mice treated with amphotericin B (positive control group) as well as imatinib 50 mg/kg compared to the unreceived drug, negative control group (P<0.05). This study could be promising in gaining insight into the potential of imatinib as an effective treatment approach against CL.
The study of solutions to superlinear problems driven by the double phase operator is a new and important topic, since it sheds light on a range of applications in the field of mathematical physics such as elasticity theory, strongly anisotropic materials, Lavrentiev's phenomenon, etc. (see [1,2,3]).
In the present paper, we study the existence and multiplicity of solutions for the following double–phase problems with mixed boundary conditions:
{D(u)+|u|p(x)−2u+b(x)|u|q(x)−2u=f(x,u) in Ω,u=0 on Λ1,(|∇u|p(x)−2u+b(x)|∇u|q(x)−2u)⋅ν=g(x,u) on Λ2, | (1.1) |
where Ω⊂RN(N≥2) is a bounded domain with Lipschitz boundary ∂Ω, Λ1,Λ2 are disjoint open subsets of ∂Ω such that ∂Ω=¯Λ1∪¯Λ2 and Λ1≠∅, 1<p(x)<q(x)<N for all x∈¯Ω, b:¯Ω↦[0,+∞) is Lipschitz continuous, ν denotes the outer unit normal of Ω at the point x∈Λ2, f:Ω×R→R and g:Λ2×R→R are Carathéodory functions, and D is the double phase variable exponents operator given by
D(u):=div(|∇u|p(x)−2∇u+b(x)|∇u|q(x)−2∇u), for u∈W1,D(Ω). | (1.2) |
Note that the differential operator defined above in (1.2) is called the double phase operator with variable exponents, which is a natural generalization of the classical double phase operator when p and q are constant functions
u↦div(|∇u|p−2∇u+b(x)|∇u|q−2∇u). |
From the physical point of view, while studying the behavior of strongly anisotropic materials, V.V. Zhikov [2] in 1986 discovered that their hardening properties changed radically point by point, what is known as the Lavrentiev phenomenon [3]. To describe this phenomenon, he initially introduced the functional
v⟼∫Ω(|∇v|p+b(x)|∇v|q)dx, | (1.3) |
where the integrand changes its ellipticity and growth properties according to the point in the domain. In the framework of mathematics, the functional (1.3) has been investigated by many authors with respect to regularity and nonstandard growth. For instance, we refer to the papers of P. Baroni et al. [4,5], P. Baroni et al. [6], G. Cupini [7], and the references therein.
Multiple authors have recently concentrated on the study of double phase problems in the case when the exponents p and q are constants, and a plethora of results have been obtained; see, for example, W. Liu and G. Dai [8], M. El Ahmadi et al. [9], L. Gasiński and P. Winkert [10], N. Cui and H.R. Sun [11], Y. Yang et al. [12], and the references therein. For example, N. Cui and H.R. Sun [11] considered the following problem in the particular case: p(x)=p, q(x)=q, and λ=1
{D(u)+|u|p−2u+b(x)|u|q−2u=f(x,u) in Ω,(|∇u|p−2u+b(x)|∇u|q−2u)⋅ν=g(x,u) on ∂Ω, |
where D(u):=div(|∇u|p−2∇u+b(x)|∇u|q−2∇u). The authors have proved the existence and multiplicity of nontrivial weak solutions for the above problem with superlinear nonlinearity. Their approach was based on critical point theory with Cerami condition.
Very recently, Y. Yang et al. [12] considered the problem (1.1) in the particular case of p(x)=p and q(x)=q. Based on the maximum principle and homological local linking, they proved the existence of at least two bounded nontrivial weak solutions.
The main novelty of the current paper is the combination of the double phase variable exponents operator with mixed boundary conditions, that is, the Dirichlet condition on Λ1 and the Steklov condition on Λ2, which is different from [13]. To the best of our knowledge, there are only a few results related to the study of such problems.
To state our results, we make the subsequent hypotheses on f and g:
(H0) There exist C1,C2>0, s1∈C+(Ω), and s2∈C+(Λ2) such that
(ⅰ) |f(x,t)|≤C1(1+|t|s1(x)−1) for all (x,t)∈Ω×R,
(ⅱ) |g(x,t)|≤C2(1+|t|s2(x)−1) for all (x,t)∈Λ2×R.
(H1) (ⅰ) 1<p+≤q+<s−1≤s+1<p∗(x) for all x∈Ω, $
(ⅱ) 1<p+≤q+<s−2≤s+2<p∗(x) for all x∈Λ2,
where
p∗(x):={Np(x)N−p(x) if p(x)<N,∞ if p(x)≥N,p∗(x):={(N−1)p(x)N−p(x) if p(x)<N,∞ if p(x)≥N.. |
(H2) (ⅰ) lim inf|t|→∞F(x,t)|t|q+=+∞ uniformly a.e. x∈Ω,
(ⅱ) lim inf|t|→∞G(x,t)|t|q+=+∞ uniformly a.e. x∈Λ2,
where F(x,t)=∫t0f(x,s)ds and G(x,t)=∫t0g(x,s)ds.
(H3) (ⅰ) There exist c1,r1≥0 and l1∈L∞(Ω) with l1(x)>Np− such as
|F(x,t)|l(x)≤c1|t|l(x)p−F(x,t), |
for all (x,t)∈Ω×R, |t|≥r1 and F(x,t):=1q+f(x,t)t−F(x,t)≥0.
(ⅱ) There exist c2,r2≥0 and l2∈L∞(Λ2) with l2(x)>N−1p−−1 such as
|G(x,t)|l(x)≤c2|t|l(x)p−G(x,t), |
for all (x,t)∈Λ2×R, |t|≥r2 and G(x,t):=1q+g(x,t)t−G(x,t)≥0.
(H4) (ⅰ) f(x,t)=∘(|t|p+−1) as t→0 uniformly for a.e. x∈Ω,
(ⅱ) g(x,t)=∘(|t|p+−1) as t→0 uniformly for a.e. x∈Λ2.
(H5) (ⅰ) f(x,−t)=−f(x,t) for all (x,t)∈Ω×R,
(ⅱ) g(x,−t)=−g(x,t) for all (x,t)∈Λ2×R.
Let us consider ϕ:X0→R the Euler functional corresponding to problem (1.1), which is defined as follows:
ϕ(u)=I(u)−φ(u), |
where
I(u)=∫Ω(1p(x)|∇u|p(x)+b(x)q(x)|∇u|q(x))dx+∫Ω(1p(x)|u|p(x)+b(x)q(x)|u|q(x))dx, |
and
φ(u)=∫ΩF(x,u)dx+∫Λ2G(x,u)dσ, |
with X0 will be defined in preliminaries and dσ is the measure on the boundary.
Then, it follows from the hypothesis (H0) that the functional ϕ∈C1(X0,R), and its Fréchet derivative is
⟨ϕ′(u),v⟩=∫Ω(|∇u|p(x)−2+b(x)|∇u|q(x)−2)∇u.∇v dx+∫Ω(|u|p(x)−2+b(x)|u|q(x)−2)u.v dx−∫Ωf(x,u)vdx−∫Λ2g(x,u)vdσ, |
for any u,v∈X0. It is clear that any critical point of ϕ is a weak solution to the problem (1.1).
Now, we present the main results of this paper.
Theorem 1. Suppose that (H0),(H1),(H2),(H3) and (H4) hold. Then problem (1.1) has at least one nontrivial weak solution.
Theorem 2. Suppose that (H0),(H1),(H2),(H3) and (H5) hold. Then problem (1.1) possesses a sequence of weak solutions (un) such that ϕ(un)→+∞ as n→+∞.
To study double phase problems, we need some definitions and basic properties of W1,D(Ω), which are called Musielak–Orlicz–Sobolev spaces. For more details, see [14,15,16,17,18,19] and references therein.
First, we recall the definition of variable exponent Lebesgue space. For p∈C+(¯Ω):={p∈C(¯Ω):p−:=infx∈¯Ωp(x)>1}, we designate the variable exponent Lebesgue space by
Lp(x)(Ω)={u:Ω→R is measurable and ∫Ω|u(x)|p(x)dx<+∞}, |
equipped with the Luxemburg norm
|u|p(x)=inf{μ>0:∫Ω|u(x)μ|p(x)dx≤1}. |
Proposition 1. [20]
1. The Sobolev space (Lp(x)(Ω),|.|p(x)) is defined as the dual space Lq(x)(Ω), where q(x) is conjugate to p(x), i.e., 1p(x)+1q(x)=1. For any u∈Lp(x)(Ω) and v∈Lq(x)(Ω), we have
|∫Ωuv dx|≤(1p−+1q−)|u|p(x)|v|q(x)≤2|u|p(x)|v|q(x). |
2. If p1,p2∈C+(¯Ω), p1(x)≤p2(x), for all x∈¯Ω, then Lp2(x)(Ω)↪Lp1(x)(Ω) and the embedding is continuous.
Let p∈C+(∂Ω):={p∈C(∂Ω):p−:=infx∈∂Ωp(x)>1} and denote by dσ the Lebesgue measure on the boundary. We define
Lp(x)(∂Ω)={u:∂Ω→R is measurable and ∫∂Ω|u|p(x)dσ<+∞}, |
with the norm
|u|p(x),∂Ω=inf{α>0:∫∂Ω|u(x)α|q(x)dσ≤1}. |
Now, we give the main properties of the Musielak–Orlicz–Sobolev functional space that we will use in the rest of this paper. Denote by N(Ω) the set of all generalized N-functions. Let us denote by
D:Ω×[0,+∞)→[0,+∞) |
the function defined as
D(x,t)=tp(x)+b(x)tq(x), for all (x,t)∈Ω×[0,+∞), |
where the weight function b(.) and the variable exponents p(.),q(.)∈C+(¯Ω) satisfies the following hypothesis:
p(x)<q(x)<N,Nq(x)N+q(x)−1<p(x) for all x∈¯Ω and 0≤b(.)∈L∞(Ω). | (2.1) |
Note that the role of assuming the inequality Nq(x)N+q(x)−1<p(x) is to ensure that q(x)<p∗(x) and q(x)<p∗(x) for all x∈¯Ω, where p∗(x)=Np(x)N−p(x) and p∗(x)=(N−1)p(x)N−p(x).
It is clear that D is a generalized N-function, locally integrable, and
D(x,2t)≤2q+D(x,t), for all (x,t)∈Ω×[0,+∞), |
which is called condition (Δ2).
We designate the Musielak–Orlicz space by
LD(Ω)={u:Ω→R is measurable and ∫ΩD(x,|u|)dx<+∞}, |
equipped with the so-called Luxemburg norm
|u|D=inf{μ>0:∫ΩD(x,|uμ|)dx≤1}. |
The Musielak–Orlicz–Sobolev space W1,D(Ω) is defined as
W1,D(Ω)={u∈LD(Ω):|∇u|∈LD(Ω)}, |
endowed with the norm
∥u∥1,D=|u|D+|∇u|D. |
With such norms, LD(Ω) and W1,D(Ω) are separable, uniformly convex, and reflexive Banach spaces.
On LD(Ω), we consider the function ρ:LD(Ω)→R defined by
ρ(u)=∫Ω(|u|p(x)+b(x)|u|q(x))dx. |
The relationship between ρ and |.|D is established by the next result.
Proposition 2. (see [16]) For u∈LD(Ω), (un)⊂LD(Ω), and μ>0, we have
1. For u≠0, |u|D=μ⟺ρ(uμ)=1;
2. |u|D<1(=1,>1)⟺ρ(u)<1(=1,>1);
3. |u|D>1⟹|u|p−D≤ρ(u)≤|u|q+D;
4. |u|D<1⟹|u|q+D≤ρ(u)≤|u|p−D;
5. limn→+∞|un|D=0⇔limn→+∞ρ(un)=0 and limn→+∞|un|D=+∞⇔limn→+∞ρ(un)=+∞.
On W1,D(Ω), we introduce the equivalent norm by
‖u‖:=inf{μ>0:∫Ω[|∇uλ|p(x)+b(x)|∇uλ|q(x)+|uλ|p(x)+b(x)|uμ|q(x)]dx≤1}. | (2.2) |
Similar to Proposition (2), we have
Proposition 3. (see [16]) Let
ˆρ(u)=∫Ω(|∇u|p(x)+b(x)|∇u|q(x))dx+∫Ω(|u|p(x)+b(x)|u|q(x))dx. |
For u∈W1,D(Ω), (un)⊂W1,D(Ω), and μ>0, we have
1. For u≠0, ‖u‖=μ⟺ˆρ(uμ)=1;
2. ‖u‖<1(=1,>1)⟺ˆρ(u)<1(=1,>1);
3. ‖u‖>1⟹‖u‖p−≤ˆρ(u)≤‖u‖q+;
4. ‖u‖<1⟹‖u‖q+≤ˆρ(u)≤‖u‖p−;
5. limn→+∞‖un‖=0⇔limn→+∞ˆρ(un)=0 and limn→+∞‖un‖=+∞⇔limn→+∞ˆρ(un)=+∞.
We recall that problem (1.1) has a mixed boundary condition. For this, our Banach space workspace is given by
X0:={u∈W1,D(Ω):u=0 on Λ2}, |
endowed with the equivalent norm (2.2). Obviously, since X0 is a closed subspace of W1,D(Ω), then (X0,‖.‖) is a reflexive Banach space.
Proposition 4. (see [16]) Let hypothesis (2.1) be satisfied. Then the following embeddings hold:
1. There is a continuous embedding LD(Ω)↪Lr(x)(Ω) for r∈C(¯Ω) with 1≤r(x)≤p(x) for all x∈¯Ω.
2. There is a compact embedding W1,D(Ω)↪Lr(x)(Ω) for r∈C(¯Ω) with 1≤r(x)<p∗(x) for all x∈¯Ω.
3. If p∈C+(¯Ω)∩W1,γ(Ω)for someγ≥N. Then, there is a continuous embedding W1,D(Ω)↪Lr(x)(∂Ω) for r∈C(∂Ω) with 1≤r(x)≤p∗(x) for all x∈∂Ω.
4. There is a compact embedding W1,D(Ω)↪Lr(x)(∂Ω) for r∈C(∂Ω) with 1≤r(x)<p∗(x) for all x∈∂Ω.
It is important to note that when we replace W1,D(Ω) by X0 in Proposition 4, the embeddings 2 and 4 remain valid.
Let A:W1,D(Ω)→(W1,D(Ω))∗ be defined by
⟨A(u),v⟩=∫Ω(|∇u|p(x)−2+b(x)|∇u|q(x)−2)∇u.∇vdx+∫Ω(|u|p(x)−2+b(x)|u|q(x)−2)u.vdx, |
for all u,v∈W1,D(Ω), where (W1,D(Ω))∗ denotes the dual space of W1,D(Ω) and ⟨.,.⟩ stands for the duality pairing between W1,D(Ω) and (W1,D(Ω))∗.
Proposition 5. (see [16,Proposition 3.4]) Let hypothesis (2.1) be satisfied.
1. A:W1,D(Ω)→(W1,D(Ω))∗ is a continuous, bounded, and strictly monotone operator.
2. A:W1,D(Ω)→(W1,D(Ω))∗ satisfies the (S+)-property, i.e., if un⇀u in W1,D(Ω) and ¯limn→+∞⟨A(un)−A(u),un−u⟩≤0, then un→u in W1,D(Ω).
Definition 1. Let u∈X0. We say that u is a weak solution to the problem (1.1) if
∫Ω(|∇u|p(x)−2+b(x)|∇u|q(x)−2)∇u.∇v dx+∫Ω(|u|p(x)−2+b(x)|u|q(x)−2)u.v dx−∫Ωf(x,u)vdx−∫Λ2g(x,u)vdσ,=0, |
for all v∈X0.
Now, we give the definition of the Cerami condition that was first introduced by G. Cerami in [21].
Definition 2. Let (X,‖.‖) be a real Banach space and ϕ∈C1(X,R). We say that ϕ satisfies the Cerami condition (we denote (C)−condition) in X, if any sequence (un)⊂X such that (ϕ(un)) is bounded and ‖ϕ′(un)‖(1+‖un‖)→0 as n→+∞ has a strong convergent subsequence in X.
Remark 1. 1. It is clear from the above definition that if ϕ satisfies the (PS)-condition, then it satisfies the (C)-condition. However, there are functionals that satisfy the (C)-condition but do not satisfy the (PS)-condition (see [21]). Consequently, the (PS)-condition implies the (C)-condition.
2. The (C)-condition and the (PS)-condition are equivalent if ϕ is bounded below (see [22]).
Next, we present the following theorems, which will play a fundamental role in the proof of the main theorems.
Theorem 3. (see [23]) Let (X,‖.‖) be a real Banach space; ϕ∈C1(X,R) satisfies the (C)-condition; ϕ(0)=0, and the following conditions hold:
1. There exist positive constants ρ and α such that ϕ(u)≥α for any u∈X with ‖u‖=ρ.
2. There exists a function e∈X such that ‖e‖>ρ and ϕ(e)≤0.
Then, the functional ϕ has a critical value c≥α, that is, there exists u∈X such that ϕ(u)=c and ϕ′(u)=0 in X∗.
Let X be a real, reflexive, and separable Banach space. Then there exist {ej}j∈N⊂X and {e∗j}j∈N⊂X∗ such that
X=¯span{ej:j=1,2,...},X∗=¯span{e∗j:j=1,2,...}, |
and ⟨e∗i,ej⟩=1 if i=j, ⟨e∗i,ej⟩=0 if i≠j.
We denote Xj=span{ej}, Yk=⨁kj=1Xj, and Zk=¯⨁+∞j=kXj.
Theorem 4. (see [24]) Assume that X is a Banach space, and let ϕ:X→R be an even functional of class C1(X,R) that satisfies the (C)−condition. For every k∈N, there exists γk>ηk>0 such that
(A1) bk:=inf{ϕ(u):u∈Zk,‖u‖=ηk}→+∞ as k→+∞;
(A2) ck:=max{ϕ(u):u∈Yk,‖u‖=γk}≤0.
Then, ϕ has a sequence of critical values tending to +∞.
First of all, we are going to show that the functional ϕ fulfills the (C)-condition.
Lemma 3.1. If assumptions (H0),(H1),(H2) and (H3) hold, then the functional ϕ satisfies the (C)-condition.
Proof. Let (un)⊂X0 be a Cerami sequence for ϕ, namely,
(ϕ(un)) is bounded and ‖ϕ′(un)‖X∗0(1+‖un‖)→0, | (3.1) |
which implies that
sup|ϕ(un)|≤M and ⟨ϕ′(un),un⟩=∘n(1), | (3.2) |
where limn→+∞∘n(1)=0 and M>0.
We need to prove the boundedness of the sequence (un) in X0. To this end, assume to the contrary, that the sequence (un) is unbounded in X0. Without loss of generality, we can assume that ‖un‖>1. By virtue of (H3), for n large enough, we have
M+1≥ϕ(un)−1q+⟨ϕ′(un),un⟩=∫Ω(1p(x)|∇un|p(x)+b(x)q(x)|∇un|q(x))dx+∫Ω(1p(x)|un|p(x)+b(x)q(x)|un|q(x))dx−∫ΩF(x,un)dx−∫Λ2G(x,un)dσ+1q+∫Ωf(x,un)undx+1q+∫Λ2g(x,un)undσ−1q+∫Ω(|∇un|p(x)+b(x)|∇un|q(x))dx−1q+∫Ω(|un|p(x)+b(x)|un|q(x))dx≥1q+∫Ω(|∇un|p(x)+b(x)|∇un|q(x))dx+1q+∫Ω(|un|p(x)+b(x)|un|q(x))dx−1q+∫Ω(|∇un|p(x)+b(x)|∇un|q(x))dx−1q+∫Ω(|un|p(x)+b(x)|un|q(x))dx+∫ΩF(x,un)dx+∫Λ2G(x,un)dσ, |
where F(x,un):=1q+f(x,un)un−F(x,un)≥0 and G(x,un)=1q+g(x,un)un−G(x,un)≥0.
Then, we obtain
M+1≥∫ΩF(x,un)dx+∫Λ2G(x,un)dσ, |
which implies
M+1≥∫ΩF(x,un)dx, | (3.3) |
and
M+1≥∫Λ2G(x,un)dσ. | (3.4) |
On the other hand, by Proposition 3, we have
M≥ϕ(un)=∫Ω(1p(x)|∇un|p(x)+b(x)q(x)|∇un|q(x))dx+∫Ω(1p(x)|un|p(x)+b(x)q(x)|un|q(x))dx−∫ΩF(x,un)dx−∫Λ2G(x,un)dσ≥1q+(∫Ω(|∇un|p(x)+b(x)|∇un|q(x))dx+∫Ω(|un|p(x)+b(x)|un|q(x))dx)−∫ΩF(x,un)dx−∫Λ2G(x,un)dσ≥1q+ˆρ(un)−∫ΩF(x,un)dx−∫Λ2G(x,un)dσ. |
Because ‖un‖>1, we can obtain
M≥1q+‖un‖p−−∫ΩF(x,un)dx−∫Λ2G(x,un)dσ. | (3.5) |
Since ‖un‖→+∞ as n→+∞, we deduce that
∫ΩF(x,un)dx+∫Λ2G(x,un)dσ≥1q+‖un‖p−−M→+∞ as n→+∞. | (3.6) |
Furthermore, using Proposition 3, we have
ϕ(un)=∫Ω(1p(x)|∇un|p(x)+b(x)q(x)|∇un|q(x))dx+∫Ω(1p(x)|un|p(x)+b(x)q(x)|un|q(x))dx−∫ΩF(x,un)dx−∫Λ2G(x,un)dσ≤1p−‖un‖q+−∫ΩF(x,un)dx−∫Λ2G(x,un)dσ. |
Then, we obtain
ϕ(un)+∫ΩF(x,un)dx+∫Λ2G(x,un)dσ≤1p−‖un‖q+. | (3.7) |
In view of condition (H2), there exist T1,T2>0 such that
F(x,t)>|t|q+ for all x∈Ω and |t|>T1,G(x,t)>|t|q+ for all x∈Λ2 and |t|>T2. |
Since F(x,.) and G(x,.) are continuous functions on [−T1,T1] and [−T2,T2], respectively, there exist C0,C∗0>0 such that
|F(x,t)|≤C0 for all (x,t)∈Ω×[−T1,T1],|G(x,t)|≤C∗0for all (x,t)∈Λ2×[−T2,T2]. |
Then, there exist two real numbers K and K′, such that
F(x,t)≥K for all (x,t)∈Ω×R,G(x,t)≥K′ for all (x,t)∈Λ2×R. |
Hence,
F(x,un)−K1p−‖un‖q+≥0,G(x,un)−K′1p−‖un‖q+≥0, | (3.8) |
for all (x,n)∈¯Ω×N.
Put βn=un‖un‖, so ‖βn‖=1. Up to subsequences, for some β∈X0, we have
βn⇀β in X0,βn→β in Ls(x)(Ω),βn→β in Lr(x)(Λ2),βn(x)→β(x) a.e., in Ω,βn(x)→β(x) a.e., in Λ2, | (3.9) |
for s(x)<p∗(x) and r(x)<p∗(x).
Define the sets Ω0={x∈Ω:β(x)≠0} and Γ={x∈Λ2:β(x)≠0}.
Obviously, since ‖un‖→+∞ as n→+∞, we have
|un(x)|=|βn(x)|‖un‖→+∞, |
for any x∈Ω0∪Γ.
Therefore, due to (H2), for all x∈Ω0∪Γ, we deduce
F(x,un)1p−‖un‖q+=p−F(x,un)|un(x)|q+|βn(x)|q+→+∞,G(x,un)1p−‖un‖q+=p−G(x,un)|un(x)|q+|βn(x)|q+→+∞. | (3.10) |
Thus, |Ω0|=0 and |Γ|=0. In fact, suppose by contradiction that |Ω0|≠0 or |Γ|≠0. Using (3.6), (3.7), (3.10), and Fatou's lemma, we get
1=lim infn→+∞ ∫ΩF(x,un)dx+∫Λ2G(x,un)dσϕ(un)+∫ΩF(x,un)dx+∫Λ2G(x,un)dσ≥lim infn→+∞∫ΩF(x,un)dx+∫Λ2G(x,un)dσ1p−‖un‖q+≥lim infn→+∞[∫Ω0F(x,un)1p−‖un‖q+dx+∫ΓG(x,un)1p−‖un‖q+dσ]−lim supn→+∞∫Ω0K1p−‖un‖q+dx−lim supn→+∞∫ΓK′1p−‖un‖q+dσ≥lim infn→+∞∫Ω0F(x,un)1p−‖un‖q+dx+lim infn→+∞∫ΓG(x,un)1p−‖un‖q+dσ−lim supn→+∞∫Ω0K1p−‖un‖q+dx−lim supn→+∞∫ΓK′1p−‖un‖q+dσ=lim infn→+∞∫Ω0F(x,un)−K1p−‖un‖q+dx+lim infn→+∞∫Γg(x,un)−K′1p−‖un‖q+dσ≥∫Ω0lim infn→+∞F(x,un)−K1p−‖un‖q+dx+∫Γlim infn→+∞G(x,un)−K′1p−‖un‖q+dσ≥∫Ω0lim infn→+∞F(x,un)1p−‖un‖q+dx+∫Γlim infn→+∞G(x,un)1p−‖un‖q+dσ−∫Ω0lim supn→+∞K1p−‖un‖q+dx−∫Γlim supn→+∞K′1p−‖un‖q+dx=+∞, |
which is a contradiction. Therefore, β(x)=0 for a.e. x∈Ω and for a.e. x∈Λ2.
From (3.5) and (3.9), respectively, we can deduce that
βn→0 in Ls(x)(Ω),βn→0 in Lr(x)(Λ2),βn(x)→0 a.e. in Ω,βn(x)→0 a.e. in Λ2, | (3.11) |
for s(x)<p∗(x), r(x)<p∗(x), and
0<1q+≤lim supn→+∞[∫Ω|F(x,un)|‖un‖p−dx+∫Λ2|G(x,un)|‖un‖p−dσ]≤lim supn→+∞∫Ω|F(x,un)|‖un‖p−dx+lim supn→+∞∫Λ2|G(x,un)|‖un‖p−dσ. | (3.12) |
Using (H0) and (H1), we obtain
∫{0≤|un(x)|≤r1}|F(x,un)|‖un‖p− dx≤C1∫{0≤|un(x)|≤r1}|un|+1s1(x)|un|s(x)‖un‖p− dx≤C1|un|1‖un‖p−+C1s−1∫{0≤|un(x)|≤r1}|un|s1(x)−p−|βn|p−dx≤C1C3‖un‖‖un‖p−+Crs−p−1s−|βn|p−p−≤CC3‖un‖p−−1+C1C4rs−p−1s−1‖βn‖p−→0, as n→+∞, | (3.13) |
where C3,C4>0, s is either s+1 or s−1 and r1 comes from (H3).
Put l′1(x)=l(x)l(x)−1. Since l1∈L∞(Ω) with l1(x)>Np−, it follows that l′1(x)p−<p∗(x).
On the other hand, by virtue of hypothesis (H3)(i), (3.3), and (3.11), we deduce
∫{|un(x)|≥r1}|F(x,un)|‖un‖p−dx≤2[∫{|un(x)|≥r1}(|F(x,un)||un|p−)l1(x)dx]1l1(x)[∫{|un(x)|≥r1}|βn|l′1(x)p−dx]1l′1(x)≤2c1l1(x)1[∫{|un(x)|≥r1}F(x,un)dx]1l1(x)[∫{|un(x)|≥r1}|βn|l′1(x)p−dx]1l′1(x)≤2c1l1(x)1[∫ΩF(x,un)dx]1l1(x)[∫Ω|βn|l′1(x)p−dx]1l′1(x)≤2c1l1(x)1(M+1)1l(x)[∫Ω|βn|l′(x)p− dx]1l′(x)→0 as n→+∞. |
Combining this with (3.13), we obtain
∫Ω|F(x,un)|‖un‖p−dx=∫{0≤|un(x)|≤r1}|F(x,un)|‖un‖p−dx+∫{|un(x)|≥r1}|F(x,un)|‖un‖p−dx⟶0, as n→+∞. | (3.14) |
Similarly, let l′2(x)=l2(x)l2(x)−1. Since l2∈L∞(Ω) with l2(x)>N−1p−−1, it follows that l′2(x)p−<p∗(x). Then, by (H3)(ii), (3.4), and (3.11), we can prove in a similar way that
∫Λ2|G(x,un)|‖un‖p−dσ⟶0, as n→+∞. | (3.15) |
Consequently, combining (3.14) with (3.15), we obtain
∫Ω|F(x,un)|‖un‖p−dx+∫Λ2|G(x,un)|‖un‖p−dσ⟶0, as n→+∞, |
which is a contradiction to (3.12). Thus, (un) is bounded in X0.
Finally, we need to prove that any (C)-sequence has a convergent subsequence. Let (un)⊂X0 be a (C)-sequence. Then, (un) is bounded in X0. Passing to the limit, if necessary, to a subsequence, from Proposition 4, we have
un⇀u in X0, un→u in Ls1(x)(Ω), un→u in Ls2(x)(Λ2),un(x)→u(x) a.e. x∈Ω, un(x)→u(x) a.e. x∈Λ2, | (3.16) |
for 1≤s1(x)<p∗(x) and 1≤s2(x)<p∗(x). It is easy to check from (H0), (3.16) and Hölder's inequality that
|∫Ωf(x,un)(un−u)dx|≤C1|1+|un|s1(x)−1|s′1(x)|un−u|s1(x)⟶0 as n→+∞, | (3.17) |
and
|∫Λ2g(x,un)(un−u)dσ|≤C2|1+|un|s2(x)−1|s′2(x)|un−u|s2(x)⟶0 as n→+∞, | (3.18) |
where 1s1(x)+1s′1(x)=1 and 1s2(x)+1s′2(x)=1.
Next, since un⇀u, from (3.1), we have
⟨ϕ′(un),un−u⟩⟶0, as n→+∞. | (3.19) |
Then
⟨ϕ′(un),un−u⟩=⟨A(un),un−u⟩−∫Ωf(x,un)(un−u)dx−∫Λ2g(x,un)(un−u)dσ⟶0 as n→+∞, |
where A is given in Proposition 5.
Finally, the combination of (3.17), (3.18), and (3.19) implies
⟨A(un),un−u⟩⟶0 as n→+∞. |
Since the operator A satisfies the (S+) property in view of Proposition 5, we can obtain that un→u in X0. The proof is complete.
Proof of Theorem 1
Let us check that the functional ϕ satisfies the geometric conditions of the mountain pass in Theorem 3. By Lemma 3.1, ϕ satisfies the (C)−condition. According to the definition of ϕ, we have ϕ(0)=0. Then, to apply Theorem 3, it remains to prove that
(ⅰ) There exist positive constants ρ and α such that ϕ(u)≥α for any u∈X0 with ‖u‖=ρ.
(ⅱ) There exists a function e∈X0 such that ‖e‖>ρ and ϕ(e)≤0.
For (i), let ‖u‖<1. Then, by Proposition 3, we have
ϕ(u)≥1p+ˆρ(u)−∫ΩF(x,u)dx−∫Λ2G(x,u)dσ≥1p+‖u‖q+−∫ΩF(x,u)dx−∫Λ2G(x,u)dσ. | (3.20) |
Using (H0) and (H4), for ε>0 be small enough, there exist C1(ε),C2(ε)>0 such that
F(x,t)≤ε|t|p++C1(ε)|t|s1(x),∀(x,t)∈Ω×R,G(x,t)≤ε|t|p++C2(ε)|t|s2(x),∀(x,t)∈Λ2×R. | (3.21) |
Since p+<s1(x)<p∗(x) and p+<s2(x)<p∗(x) for all x∈¯Ω and for all x∈¯Λ2 in view of condition (H1), we have from Proposition 4 that
X0↪Lp+(Ω),X0↪Ls1(x)(Ω),X0↪Lp+(Λ2),X0↪Ls2(x)(Λ2). |
So, there exist ci>0(i=3,...6) such that
|u|p+≤c3‖u‖,|u|s1(x)≤c4‖u‖, ∀u∈X0|u|p+,Λ2≤c6‖u‖,|u|s(x)≤c7‖u‖, ∀u∈X0. |
Therefore, by (3.20) and (3.21), for ‖u‖<1 sufficiently small, we obtain
ϕ(u)⩾1q+‖u‖q+−ε∫Ω|u|p+dx−C1(ε)∫Ω|u|s1(x)dx−ε∫Λ2|u|p+dσ−C2(ε)∫Λ2|u|s2(x)dσ⩾1q+‖u‖q+−εcp+3‖u‖p+−C1(ε)cs−14‖u‖s−1−εcp+5‖u‖p+−C2(ε)cs−26‖u‖s−2. |
Since s−1>p+ in view of condition (H1) and ‖u‖<1, then ‖u‖s−1<‖u‖p+. Thus, we obtain
ϕ(u)⩾1q+‖u‖q+−εcp+3‖u‖p+−C1(ε)cs−14‖u‖p+−εcp+5‖u‖p+−C2(ε)cs−26‖u‖s−2≥1q+‖u‖q+−(εcp+3+C1(ε)cs−14+εcp+5)‖u‖p+−C2(ε)cs−26‖u‖s−2. |
Since s−2>q+≥p+, then by the standard argument, there exist positive constants ρ and α such that ϕ(u)≥α for any u∈X0 with ‖u‖=ρ.
Next, we affirm that there exists e∈X0 with ‖u‖>ρ such that
ϕ(e)<0. | (3.22) |
In fact, from (H2), it follows that for every k>0, there exist constants Tk and T∗k such that
F(x,t)>k|t|q+ for all x∈Ω and |t|>Tk,G(x,t)>k|t|q+ for all x∈Λ2 and |t|>T∗k. |
Since F(x,.) and G(x,.) are continuous functions on [−Tk,Tk] and [−T∗k,T∗k], respectively, there exist constants C0,C∗0>0 such that
|F(x,t)|≤C0 for all (x,t)∈Ω×[−Tk,Tk],|G(x,t)|≤C∗0 for all (x,t)∈Λ2×[−T∗k,T∗k]. |
Thus,
F(x,t)≥k|t|q+−C0, for all (x,t)∈Ω×R,G(x,t)≥k|t|q+−C∗0, for all (x,t)∈Λ2×R. | (3.23) |
Let w∈X0∖{0} such that ‖w‖=1 and l>1 be large enough. Using the above inequality, we obtain
ϕ(lw)=∫Ω(1p(x)|∇lw|p(x)+b(x)q(x)|∇lw|q(x))dx+∫Ω(1p(x)|lw|p(x)+b(x)q(x)|lw|q(x))dx−∫ΩF(x,lw)dx−∫Λ2G(x,lw)dσ≤lq+p−ˆρ(w)−klq+∫Ω|w|q+dx−klq+∫Λ2|w|q+dσ+C0|Ω|+C∗0|Λ2|≤lq+p−−klq+∫Ω|w|q+dx−klq+∫Λ2|w|q+dσ+C0|Ω|+C∗0|Λ2|=lq+(1p−−k∫Ω|w|q+dx−k∫Λ2|w|q+dσ)+C0|Ω|+C∗0|Λ2|. |
As
1p−−k∫Ω|w|q+dx−k∫Λ2|w|q+dσ<0, |
for k large enough, we deduce
ϕ(lw)→−∞, as l→+∞. |
Thus, there exist t0>1 and e=t0w∈X0∖¯Bρ(0) such that ϕ(e)<0.
Proof of Theorem 2
To prove Theorem 2, we need the following auxiliary lemmas:
Lemma 3.2. (see [25,26]) For s∈C+(¯Ω) and r∈C+(¯Λ2) such that s(x)<p∗(x) for all x∈¯Ω and r(x)<p∗(x) for all x∈¯Λ2. Let
δk=sup{|u|s(x):‖u‖=1,u∈Zk},δ′k=sup{|u|s(x),Λ2:‖u‖=1,u∈Zk}. |
Then, limk→+∞δk=limk→+∞δ′k=0.
Lemma 3.3. (see [27]) For all s∈C+(¯Ω) (r∈C+(¯Λ2)) and u∈Ls(x)(Ω) (v∈Lr(x)(Λ2)), there exists y∈Ω (z∈Λ2) such that
∫Ω|u|s(x)dx=|u|s(y)s(x),∫Λ2|u|r(x)dσ=|u|r(z)r(x),Λ2. | (3.24) |
Now, we return to the proof of Theorem 2. To this end, based on Fountain Theorem 4, we will show that the problem (1.1) possesses infinitely many weak solutions with unbounded energy. Evidently, according to (H5), ϕ is an even functional. By Lemma 3.1, we know that ϕ satisfies the (C)-condition. Then, to prove Theorem 2, it only remains to verify the following assertions:
(A1) bk:=inf{ϕ(u):u∈Zk,‖u‖=ηk}→+∞ as k→+∞,
(A2) ck:=max{ϕ(u):u∈Yk,‖u‖=γk}≤0.
(A1) For any u∈Zk such that ‖u‖=ηk>1. It follows from (H0), Proposition 3, and Lemma 3.3 that
ϕ(u)=∫Ω(1p(x)|∇u|p(x)+b(x)q(x)|∇u|q(x))dx+∫Ω(1p(x)|u|p(x)+b(x)q(x)|u|q(x))dx−∫ΩF(x,u)dx−∫Λ2G(x,u)dσ≥1q+‖u‖p−−C1∫Ω|u|dx−C1∫Ω|u|s1(x)s1(x)dx−C2∫Λ2|u|dσ−C2∫Λ2|u|s2(x)s2(x)dσ≥1q+‖u‖p−−C1c1‖u‖−C1s−1|u|s1(y)s1(x)−C2c2‖u‖−C2s−2|u|s2(z)s2(x),λ2≥1q+‖u‖p−−c3‖u‖−C1s−1|u|s1(y)s1(x)−C2s−2|u|s2(z)s2(x),λ2, |
where c3=max{C1c1,C2c2}.
Then, it follows that
ϕ(u)≥{1q+‖u‖p−−c3‖u‖−C1s−1−C2s−2 if |u|s1(x)≤1,|u|s2(x)≤11q+‖u‖p−−c3‖u‖−C1s−1(δk‖u‖)s+1−C2s−2(δ′k‖u‖)s+2 if |u|s1(x)>1,|u|s2(x)>11q+‖u‖p−−c3‖u‖−C1s−1−C2s−2(δ′k‖u‖)s+2 if |u|s1(x)≤1,|u|s2(x)>11q+‖u‖p−−c3‖u‖−C1s−1(δk‖u‖)s+1−C2s−2 if |u|s1(x)>1,|u|s2(x)≤1≥1q+‖u‖p−−c3‖u‖−2C1s−1(δk‖u‖)s+1−2C2s−2(δ′k‖u‖)s+2−2C1s−1−2C2s−2≥12q+‖u‖p−+(14q+‖u‖p−−2C1s−1δs+1k‖u‖s+1)+(14q+‖u‖p−−2C1s−2(δ′k)s+2‖u‖s+2)−c3‖u‖−2C1s−1−2C2s−2. | (3.25) |
Let us consider the following equations:
14q+tp−−2C1s−1δs+1kts+1=0, | (3.26) |
and
14q+tp−−2C1s−2(δ′k)s+2ts+2=0. | (3.27) |
Let ak and dk be the two non-zero solutions of (3.26) and (3.27), respectively. Then, we obtain
ak=(4q+2C1s−1δs+1k)1p−−s+1→+∞ and dk=(4q+2C2s−2(δ′k)s+2)1p−−s+2→+∞ as k→+∞. |
We fix ηk as follows
ηk=min{ak,dk}. |
Then, by Lemma 3.2, (3.25) and s+1,s+2>q+>p−, we obtain
ϕ(u)≥12q+ηp−k−c3ηk−C6→+∞ as k→+∞, |
where C6>0. Hence, (A1) holds.
(A2) In view of Proposition 3 and (3.23), for u∈Yk with ‖u|>1, we have
ϕ(u)≤1p−‖u‖q+−∫ΩF(x,u)dx−∫Λ2G(x,u)dσ≤1p−‖u‖q+−k∫Ω|u|q+dx−k∫Λ2|u|q+dσ+C0|Ω|+C∗0|Λ2|≤1p−‖u‖q+−k(|u|q+q++|u|q+q+,Λ2)+C0|Ω|+C∗0|Λ2|. |
Since dimYk<∞, then all norms are equivalent in Yk. Therefore, as 1p−<1, for k large enough, we obtain
ϕ(u)→−∞ as ‖u‖→+∞. |
Finally, the assertion (A2) is also valid.
This completes the proof.
Mahmoud El Ahmadi: Writing-original draft, Writing-review & editing; Mohammed Barghouthe: Formal Analysis, Methodology; Anass Lamaizi: Formal Analysis; Mohammed Berrajaa: Supervision, Validation.
The authors declare they have not used Artificial Intelligence (AI) tools in the creation of this article.
The authors would like to thank the referees for their valuable comments and suggestions, which have improved the quality of this paper.
The authors declare there is no conflict of interest.
[1] |
Ghorbani M, Farhoudi R (2018) Leishmaniasis in humans: drug or vaccine therapy? Drug Des Devel Ther 12: 25-40. doi: 10.2147/DDDT.S146521
![]() |
[2] | Lindoso JA, Cunha MA, Queiroz IT, et al. (2016) Leishmaniasis–HIV coinfection: current challenges. HIV/AIDS 8: 147. |
[3] |
Bahrami F, Harandi AM, Rafati S (2018) Biomarkers of cutaneous leishmaniasis. Front Cell Infect Microbiol 8: 222. doi: 10.3389/fcimb.2018.00222
![]() |
[4] |
Mendonça SC (2016) Differences in immune responses against Leishmania induced by infection and by immunization with killed parasite antigen: implications for vaccine discovery. Parasites Vectors 9: 492. doi: 10.1186/s13071-016-1777-x
![]() |
[5] |
Apostolopoulos N, Mitropoulou A, Thom N, et al. (2018) Update on therapy and prevention of canine leishmaniasis. Tierarztl Prax Ausg K Kleintiere Heimtiere 46: 315-322. doi: 10.15654/TPK-180089
![]() |
[6] | Kaiming B, Yuyang C, Songnian Z, et al. (2018) Current visceral leishmaniasis research: a research review to inspire future study. BioMed Res Intl 2018: 1-13. |
[7] |
Norouzinezhad F, Ghaffari F, Norouzinejad A, et al. (2016) Cutaneous leishmaniasis in Iran: Results from an epidemiological study in urban and rural provinces. Asian Pac J Trop Biomed 6: 614-619. doi: 10.1016/j.apjtb.2016.05.005
![]() |
[8] |
Adriaensen W, Dorlo TPC, Guido V, et al. (2018) Immunomodulatory therapy of visceral leishmaniasis in human immunodeficiency virus-coinfected patients. Front Immunol 8: 1943. doi: 10.3389/fimmu.2017.01943
![]() |
[9] |
de Vries HJ, Reedijk SH, Schallig HD (2015) Cutaneous leishmaniasis: recent developments in diagnosis and management. Am J Clin Dermatol 16: 99-109. doi: 10.1007/s40257-015-0114-z
![]() |
[10] |
Alcântara LM, Ferreira TCS, Gadelha FR, et al. (2018) Challenges in drug discovery targeting TriTryp diseases with an emphasis on leishmaniasis. Int J Parasitol Drugs Drug Resist 8: 430-439. doi: 10.1016/j.ijpddr.2018.09.006
![]() |
[11] |
Hotez PJ, Bottazzi ME, Strych U (2016) New vaccines for the world's poorest people. Annu Rev Med 67: 405-417. doi: 10.1146/annurev-med-051214-024241
![]() |
[12] |
Moen MD, McKeage K, Plosker GL, et al. (2007) Imatinib: a review of its use in chronic myeloid leukaemia. Drugs 67: 299-320. doi: 10.2165/00003495-200767020-00010
![]() |
[13] |
O'Connell EM, Bennuru S, Steel C, et al. (2015) Targeting Filarial Abl-like Kinases: Orally Available, Food and Drug Administration–Approved Tyrosine Kinase Inhibitors Are Microfilaricidal and Macrofilaricidal. Int J Infect Dis 212: 684-693. doi: 10.1093/infdis/jiv065
![]() |
[14] |
Kesely KR, Pantaleo A, Turrini FM, et al. (2016) Inhibition of an erythrocyte tyrosine kinase with imatinib prevents Plasmodium falciparum egress and terminates parasitemia. PloS one 11. doi: 10.1371/journal.pone.0164895
![]() |
[15] |
Alvarez-Rueda N, Biron M, Le Pape (2009) Infectivity of Leishmania mexicana is associated with differential expression of protein kinase C-like triggered during a cell-cell contact. PLoS One 4. doi: 10.1371/journal.pone.0007581
![]() |
[16] |
Hodgson J (2001) ADMET—turning chemicals into drugs. Nat Biotechnol 19: 722-726. doi: 10.1038/90761
![]() |
[17] |
Potts RO, Guy RH (1992) Predicting skin permeability. Pharm Res 9: 663-669. doi: 10.1023/A:1015810312465
![]() |
[18] | Moslehi M, Namdar F, Esmaeilifallah M, et al. (2019) Evaluation of different concentrations of imatinib on the viability of Leishmania major: An In Vitro study. Adv Biomed Res 8. |
[19] |
Ponte-Sucre A, Gamarro F, Dujardin JC, et al. (2017) Drug resistance and treatment failure in leishmaniasis: A 21st century challenge. PLoS Negl Trop Dis 11. doi: 10.1371/journal.pntd.0006052
![]() |
[20] |
Vakili B, Eslami M, Hatam GR, et al. (2018) Immunoinformatics-aided design of a potential multi-epitope peptide vaccine against Leishmania infantum. Int J Biol Macromol 120: 1127-1139. doi: 10.1016/j.ijbiomac.2018.08.125
![]() |
[21] |
Scott P, Novais FO (2016) Cutaneous leishmaniasis: immune responses in protection and pathogenesis. Nat Rev Immunol 16: 581-592. doi: 10.1038/nri.2016.72
![]() |
[22] |
Vakili B, Nezafat N, Zare B, et al. (2020) A new multi-epitope peptide vaccine induces immune responses and protection against Leishmania infantum in BALB/c mice. Med Microbiol Immunol 209: 69-79. doi: 10.1007/s00430-019-00640-7
![]() |
[23] |
Bekhit AA, El-Agroudy E, Helmy A, et al. (2018) Leishmania treatment and prevention: Natural and synthesized drugs. Eur J Med Chem 160: 229-244. doi: 10.1016/j.ejmech.2018.10.022
![]() |
[24] |
Vakili B, Nezafat N, Hatam GR, et al. (2018) Proteome-scale identification of Leishmania infantum for novel vaccine candidates: A hierarchical subtractive approach. Comput Biol Chem 72: 16-25. doi: 10.1016/j.compbiolchem.2017.12.008
![]() |
[25] |
Kennedy JA, Hobbs G (2018) Tyrosine kinase inhibitors in the treatment of chronic-phase CML: Strategies for frontline decision-making. Curr Hematol Malig Rep 13: 202-211. doi: 10.1007/s11899-018-0449-7
![]() |
[26] |
Katz N, Couto FFB, Araújo N (2013) Imatinib activity on Schistosoma mansoni. Mem Inst Oswaldo Cruz 108: 850-853. doi: 10.1590/0074-0276130207
![]() |
[27] |
Beckmann S, Long T, Scheld C, et al. (2014) Serum albumin and α-1 acid glycoprotein impede the killing of Schistosoma mansoni by the tyrosine kinase inhibitor Imatinib. Int J Parasitol Drugs Drug Resist 4: 287-295. doi: 10.1016/j.ijpddr.2014.07.005
![]() |
[28] |
Naula C, Parsons M, Mottram JC (2005) Protein kinases as drug targets in trypanosomes and Leishmania. Biochim Biophys Acta 1754: 151-159. doi: 10.1016/j.bbapap.2005.08.018
![]() |
[29] |
Handman E, Bullen DV (2002) Interaction of Leishmania with the host macrophage. Trends Parasitol 18: 332-334. doi: 10.1016/S1471-4922(02)02352-8
![]() |
[30] |
Sanderson L, Yardley V, Croft SL (2014) Activity of anticancer protein kinase inhibitors against Leishmania spp. J Antimicrob Chemother 69: 1888-1891. doi: 10.1093/jac/dku069
![]() |
[31] |
Matsushita M, Kawaguchi M (2018) Immunomodulatory effects of drugs for effective cancer immunotherapy. J Oncol 2018. doi: 10.1155/2018/8653489
![]() |
[32] |
Hahn T, Polanczyk MJ, Borodovsky A, et al. (2013) Use of anticancer drugs, mitocans, to enhance the immune responses against tumors. Curr Pharm Biotechnol 14: 357-376. doi: 10.2174/1389201011314030010
![]() |
[33] |
Al-Abdely HM, Graybill JR, Bocanegra R, et al. (1998) Efficacies of KY62 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous leishmaniasis and visceral leishmaniasis. Antimicrob Agents Chemother 42: 2542-2548. doi: 10.1128/AAC.42.10.2542
![]() |
[34] | Dahiya M, Dureja H (2016) Central composite designed imatinib-loaded magnetic nanoparticles. Recent Pat Nanotechnol 6: 146-155. |